Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7186 to 7200 of 8905 results

  1. Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices (DG61)

    We have moved Diagnostics guidance 61 to become HealthTech guidance 730. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  2. EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)

    We have moved Diagnostics guidance 9 to become HealthTech guidance 316. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  3. SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant irritable bowel syndrome (IBS-D) or Crohn's disease without ileal resection (DG7)

    This guidance has been updated and replaced by NICE healthtech guidance 598.

    Withdrawn guidance

  4. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment (HTE10)

    We have moved health technology evaluation 10 to become HealthTech guidance 694. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  5. Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections (HTE1)

    We have moved HTE1 to become 'antimicrobial resistance guidance'. This is to better reflect what the purpose of this product is and to help you find relevant content more quickly. The guidance itself has not changed. See antimicrobial resistance guidance 1 on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.

    Withdrawn guidance

  6. Artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment (HTE12)

    We have moved health technology evaluation 12 to become HealthTech guidance 696. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  7. Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment (HTE11)

    We have moved health technology evaluation 11 to become HealthTech guidance 695. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  8. Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment (HTE15)

    We have moved health technology evaluation 15 to become HealthTech guidance 701. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  9. Microstructural scaffold (patch) insertion without autologous cell implantation for repairing symptomatic chondral knee defects (IPG560)

    This guidance has been updated and replaced by NICE HealthTech guidance 728.

    Withdrawn guidance

  10. Computed tomography-guided thermocoagulation of osteoid osteoma (IPG53)

    We have moved interventional procedures guidance 53 to become HealthTech guidance 27. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  11. Low energy contact X-ray brachytherapy (the Papillon technique) for early stage rectal cancer (IPG532)

    This guidance has been updated and replaced by NICE HealthTech guidance 763.

    Withdrawn guidance

  12. Endovascular aneurysm sealing for abdominal aortic aneurysm (IPG547)

      March 2019: We have withdrawn the guidance because the CE mark for the Nellix Endovascular Aneurysm Sealing (EVAS) System has been withdrawn. Endologix is recalling unused stock. The MHRA recommends enhanced patient surveillance (see MDA/2019/002) because of a high risk of the graft failing beyond 2 years after implantation.

    Withdrawn guidance

  13. Transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting (IPG561)

    We have moved interventional procedures guidance 561 to become HealthTech guidance 415. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  14. Implanting a baroreceptor stimulation device for resistant hypertension (IPG533)

    We have moved interventional procedures guidance 533 to become HealthTech guidance 387. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  15. Transcranial direct current stimulation (tDCS) for depression (IPG530)

    We have moved interventional procedures guidance 530 to become HealthTech guidance 382. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance